Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer

Bone Marrow Transplantation volume 44, pages 81–87 (2009)Cite this article

Abstract

We found earlier that high-dose chemotherapy with Allo-SCT produced a tumor response in patients with chemorefractory metastatic breast cancer. In this study, we examined the efficacy and toxicity of nonmyeloablative allogeneic PBSC transplantation in patients with chemosensitive metastatic breast cancer. Twelve patients with metastatic breast carcinoma who had stable disease after standard-dose chemotherapy and six who had a partial response underwent allogeneic transplantation. The conditioning regimen consisted of reduced-intensity fludarabine and melphalan. All patients achieved engraftment and hematopoietic recovery. Nine patients developed grade II or higher acute GVHD; seven of these nine responded to immunosuppressive therapy. Fourteen patients developed chronic GVHD. The treatment-related mortality rate was 11%. With a median follow-up of 565 days, the median survival duration was 643 days and the median progression-free survival duration was 202 days. Two patients are alive with a complete response 1555 and 2526 days after SCT, and one patient is alive with progressive bone disease at day 1118. We conclude that among patients with chemotherapy-sensitive metastatic breast cancer, a fraction will achieve a durable complete response after SCT with a reduced-intensity conditioning regimen. The question remains how to improve the overall efficacy and reduce the mortality rate for this approach.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Hortobagyi GN . Can we cure limited metastatic breast cancer? J Clin Oncol 2002; 20: 620–623.

    Article  PubMed  Google Scholar 

  2. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU . Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–2205.

    Article  CAS  PubMed  Google Scholar 

  3. Ben-Yosef R, Or R, Nagler A, Slavin S . Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 1996; 348: 1242–1243.

    Article  CAS  PubMed  Google Scholar 

  4. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–1508.

    CAS  PubMed  Google Scholar 

  5. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986–993.

    Article  CAS  PubMed  Google Scholar 

  6. Moscovitch M, Slavin S . Anti-tumor effects of allogeneic bone marrow transplantation in (NZB × NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol 1984; 132: 997–1000.

    CAS  PubMed  Google Scholar 

  7. Prigozhina TB, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S . Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol 2002; 30: 89–96.

    Article  PubMed  Google Scholar 

  8. Blaise D, Bay JO, Faucher C, Michallet M, Boiron J-M, Choufi B et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435–441.

    Article  CAS  PubMed  Google Scholar 

  9. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I . Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234–4236.

    Article  CAS  PubMed  Google Scholar 

  10. Carella AM, Beltrami G, Lerma E, Cavaliere M, Corsetti MT . Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer. Cancer Treat Res 2002; 110: 101–112.

    Article  PubMed  Google Scholar 

  11. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829–3836.

    Article  CAS  PubMed  Google Scholar 

  12. Schwartz DW, Glock B, Jungl EM, Mayr WR . Strategy to detect chimerism in allogeneic bone marrow transplant recipients by PCR-amplification fragment length polymorphism analysis of microsatellite polymorphisms. Vox Sang 1995; 68: 139–143.

    Article  CAS  PubMed  Google Scholar 

  13. Yam PY, Petz LD, Knowlton RG, Wallace RB, Stock AD, de Lange G et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987; 43: 399–407.

    Article  CAS  PubMed  Google Scholar 

  14. An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature. Birth Defects: Orig Artic Ser 1985; 21: 1–117.

    Google Scholar 

  15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  16. Imanguli MM, Childs RW . Hematopoietic stem cell transplantation for solid tumors. Update Cancer Ther 2006; 1: 343–352.

    Article  Google Scholar 

  17. Oblon DJ, Paul S, Yankee R . Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE). Bone Marrow Transplant 1997; 20: 421–423.

    Article  CAS  PubMed  Google Scholar 

  18. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318–320.

    Article  PubMed  Google Scholar 

  19. Carella AM, Bregni M . Current role of allogeneic stem cell transplantation in breast cancer. Ann Oncol 2007; 18: 1591–1593.

    Article  CAS  PubMed  Google Scholar 

  20. Carella AM, Ferrara R, Orcioni GF, Pepe G, Villavecchia G . Profound graft-versus-tumor response in metastatic breast cancer with nonmyeloablative allografting. Ann Oncol 2007; 18: 1751–1754.

    Article  CAS  PubMed  Google Scholar 

  21. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886–3892.

    Article  PubMed  Google Scholar 

  22. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant 2008; 41: 537–545.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Sunita Patterson of the Department of Scientific Publications at M.D. Anderson Cancer Center for her expert editorial assistance.

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    J A de Souza, M L Davis, G Rondon, R B Jones, R E Champlin & N T Ueno

  2. Division of Neoplastic Diseases and Related Disorders, Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

    Y C Cheng

  3. Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    N T Ueno

Authors
  1. J A de Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M L Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Rondon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y C Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R B Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R E Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N T Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N T Ueno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Souza, J., Davis, M., Rondon, G. et al. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 44, 81–87 (2009). https://doi.org/10.1038/bmt.2009.101

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.101

Keywords

This article is cited by

Search

Advanced search

Quick links